Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of Darolutamide Addition to ADT and Radiotherapy in Newly Diagnosed Prostate Cancer with Pelvic Lymph Node Metastases
2021-003542-21Phase 3Active
- Sponsor
- ARTIC
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of darolutamide in prostate cancer (PCa) (2 arms), sponsored by ARTIC. Primary endpoint: Failure-free survival. Started Sep 2024; status: active.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2021-003542-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003542-21.